| Style | Citing Format |
|---|---|
| MLA | Rostami S, et al.. "Evaluation of Specific Igg Antibody in Subjects Who Had Been Previously Infected With Sars-Cov-2." Advanced Biomedical Research, vol. 12, no. 1, 2023, pp. -. |
| APA | Rostami S, Ahangarzadeh S, Zamani Moghaddam A, Nokhodian Z, Modaresifar H, Roustaei A, Shoaei P, Rowzati M, Tahvilian Z, Nazari A, Kassaian N, Haghjooy Javanmard S, Ataei B (2023). Evaluation of Specific Igg Antibody in Subjects Who Had Been Previously Infected With Sars-Cov-2. Advanced Biomedical Research, 12(1), -. |
| Chicago | Rostami S, Ahangarzadeh S, Zamani Moghaddam A, Nokhodian Z, Modaresifar H, Roustaei A, Shoaei P, et al.. "Evaluation of Specific Igg Antibody in Subjects Who Had Been Previously Infected With Sars-Cov-2." Advanced Biomedical Research 12, no. 1 (2023): -. |
| Harvard | Rostami S et al. (2023) 'Evaluation of Specific Igg Antibody in Subjects Who Had Been Previously Infected With Sars-Cov-2', Advanced Biomedical Research, 12(1), pp. -. |
| Vancouver | Rostami S, Ahangarzadeh S, Zamani Moghaddam A, Nokhodian Z, Modaresifar H, Roustaei A, et al.. Evaluation of Specific Igg Antibody in Subjects Who Had Been Previously Infected With Sars-Cov-2. Advanced Biomedical Research. 2023;12(1):-. |
| BibTex | @article{ author = {Rostami S and Ahangarzadeh S and Zamani Moghaddam A and Nokhodian Z and Modaresifar H and Roustaei A and Shoaei P and Rowzati M and Tahvilian Z and Nazari A and Kassaian N and Haghjooy Javanmard S and Ataei B}, title = {Evaluation of Specific Igg Antibody in Subjects Who Had Been Previously Infected With Sars-Cov-2}, journal = {Advanced Biomedical Research}, volume = {12}, number = {1}, pages = {-}, year = {2023} } |
| RIS | TY - JOUR AU - Rostami S AU - Ahangarzadeh S AU - Zamani Moghaddam A AU - Nokhodian Z AU - Modaresifar H AU - Roustaei A AU - Shoaei P AU - Rowzati M AU - Tahvilian Z AU - Nazari A AU - Kassaian N AU - Haghjooy Javanmard S AU - Ataei B TI - Evaluation of Specific Igg Antibody in Subjects Who Had Been Previously Infected With Sars-Cov-2 JO - Advanced Biomedical Research VL - 12 IS - 1 SP - EP - PY - 2023 ER - |